Tyrosine kinase inhibitors for chronic myelogenous leukemia.
Defuentes
Gilles
G
Bladé
Jean-Sébastien
JS
Berets
Olivier
O
D001549:Benzamides; D016044:Fusion Proteins, bcr-abl; D006801:Humans; D007037:Hypothyroidism / Q000139:chemically induced*; D000068877:Imatinib Mesylate; D007211:Indoles / Q000009:adverse effects; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D010879:Piperazines / Q000009:adverse effects; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011743:Pyrimidines / Q000009:adverse effects; D011758:Pyrroles / Q000009:adverse effects; D000077210:Sunitinib
D001549:Benzamides; D007211:Indoles; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D011758:Pyrroles; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D016044:Fusion Proteins, bcr-abl; D000077210:Sunitinib